Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Meridian Bioscience (VIVO) Stock Price
News stories about Meridian Bioscience (NASDAQ:VIVO) have trended somewhat positive on Wednesday, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Meridian Bioscience earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.2105818823202 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Meridian Bioscience Inc. (VIVO) Set to Announce Quarterly Earnings on Thursday (americanbankingnews.com)
- Meridian Bioscience, Inc. Expects to Report Fiscal 2018 Revenue and Earnings Guidance on Thursday, October 19, 2017 (finance.yahoo.com)
- One of Cincinnati’s largest public companies names new CEO (finance.yahoo.com)
- Meridian Bioscience’s (VIVO) Hold Rating Reaffirmed at Canaccord Genuity (americanbankingnews.com)
- ETFs with exposure to Meridian Bioscience, Inc. : October 11, 2017 (finance.yahoo.com)
Meridian Bioscience (VIVO) traded up 4.01% during midday trading on Wednesday, reaching $15.55. The company’s stock had a trading volume of 177,175 shares. The firm has a 50 day moving average of $14.22 and a 200 day moving average of $14.35. Meridian Bioscience has a 52-week low of $10.75 and a 52-week high of $18.90. The firm has a market cap of $656.26 million, a P/E ratio of 31.10 and a beta of 0.84.
Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. The business had revenue of $50.14 million for the quarter, compared to analyst estimates of $49.13 million. Meridian Bioscience had a return on equity of 16.93% and a net margin of 10.77%. The company’s quarterly revenue was down 1.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.21 earnings per share. Analysts anticipate that Meridian Bioscience will post $0.67 earnings per share for the current fiscal year.
VIVO has been the topic of several recent analyst reports. BidaskClub cut Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Thursday, July 6th. Canaccord Genuity reiterated a “hold” rating and set a $14.00 price objective on shares of Meridian Bioscience in a report on Friday, October 13th. Finally, Zacks Investment Research upgraded Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Thursday, October 5th. Two equities research analysts have rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. Meridian Bioscience currently has an average rating of “Hold” and an average target price of $14.00.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Meridian Bioscience (VIVO) Stock Price” was posted by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-meridian-bioscience-vivo-stock-price/1639390.html.
In other news, Chairman John A. Kraeutler purchased 7,000 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were acquired at an average price of $13.67 per share, for a total transaction of $95,690.00. Following the completion of the acquisition, the chairman now owns 345,230 shares in the company, valued at $4,719,294.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.30% of the stock is currently owned by corporate insiders.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.